[Prognostic value of KIT and other clonal genetic mutations in core-binding factor acute myeloid leukemia].

作者：T M Wu, Shengli Xue, Z Li, Jing-Qiu Yu, J Wang, B R Wang, Chao‐Ling Wan, Xiang‐Dong Shen, Qiao‐Cheng Qiu, Xiebing Bao, Depei Wu · 发表于：PubMed · 年份：2021 · DOI：10.3760/cma.j.issn.0253-2727.2021.08.006 · 被引用次数：3 · 研究领域：Acute Myeloid Leukemia Research、Myeloproliferative Neoplasms: Diagnosis and Treatment、Chronic Myeloid Leukemia Treatments

KIT exon 17 mutations might indicate poor prognosis in patients with RUNX1-RUNXIT1(+) AML. Allo-HSCT may improve prognosis in these patients, whereas allo-HSCT might also improve prognosis in patients with mutations in genes related to chromatin modifications.